Literature DB >> 1869471

The biological basis for conformal three-dimensional radiation therapy.

S A Leibel1, C C Ling, G J Kutcher, R Mohan, C Cordon-Cordo, Z Fuks.   

Abstract

The recent introduction of new computer technology for treatment planning and computer-driven treatment delivery systems, such as multi-leaf collimators and on-line verification systems, has accelerated the development of 3-dimensional (3-D) radiation therapy as a modality for curative cancer treatment. The goal of 3-D treatment planning is to conform the spatial distribution of the high radiation dose to the shape of the tumor contour while concomitantly decreasing the volume of the surrounding normal tissues receiving high radiation doses. The improved precision of tumor coverage and the exclusion of normal tissues should permit tumor dose escalation and may enhance local tumor control. It has been suggested that any survival gains derived from improvements in local control may be offset by the subsequent appearance of distant metastases arising from micrometastases already present at the time of initial diagnosis. However, clinical and laboratory studies indicate that failure to control the primary tumor at the time of initial treatment significantly increases the incidence of metastatic dissemination. This phenomenon is consistent with the hypothesis that the enhanced mitotic activity associated with the re-growth process of locally recurring primary tumors promotes the multi-step transformation of non-metastatic tumor cells into clonogens with metastatic potential, leading to increased overall rates of metastatic disease. These biologic considerations provide support for the need to focus attention on the identification of more effective therapeutic strategies designed to eradicate the primary local tumor completely at the time of initial therapy and serve as the rationale for clinical studies using 3-D conformal radiation therapy.

Entities:  

Mesh:

Year:  1991        PMID: 1869471     DOI: 10.1016/0360-3016(91)90701-5

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

Review 1.  Radiotherapy and wound healing.

Authors:  Emma-Louise Dormand; Paul E Banwell; Timothy E E Goodacre
Journal:  Int Wound J       Date:  2005-06       Impact factor: 3.315

2.  Clinical use of a simulation-multileaf collimator.

Authors:  M Marx; P Vacha; B Riis; T Feyerabend; E Richter
Journal:  Strahlenther Onkol       Date:  1998-07       Impact factor: 3.621

3.  Single-dose radiotherapy disables tumor cell homologous recombination via ischemia/reperfusion injury.

Authors:  Sahra Bodo; Cécile Campagne; Tin Htwe Thin; Daniel S Higginson; H Alberto Vargas; Guoqiang Hua; John D Fuller; Ellen Ackerstaff; James Russell; Zhigang Zhang; Stefan Klingler; HyungJoon Cho; Matthew G Kaag; Yousef Mazaheri; Andreas Rimner; Katia Manova-Todorova; Boris Epel; Joan Zatcky; Cristian R Cleary; Shyam S Rao; Yoshiya Yamada; Michael J Zelefsky; Howard J Halpern; Jason A Koutcher; Carlos Cordon-Cardo; Carlo Greco; Adriana Haimovitz-Friedman; Evis Sala; Simon N Powell; Richard Kolesnick; Zvi Fuks
Journal:  J Clin Invest       Date:  2019-01-14       Impact factor: 14.808

Review 4.  Conversion of unresectable to resectable liver cancer: an approach and follow-up study.

Authors:  J V Sitzmann
Journal:  World J Surg       Date:  1995 Nov-Dec       Impact factor: 3.352

Review 5.  Advances in radiation technology can improve survival and quality of life for cancer patients.

Authors:  J Armstrong
Journal:  Ir J Med Sci       Date:  2001 Jan-Mar       Impact factor: 2.089

6.  Radial Data Mining to Identify Density-Dose Interactions That Predict Distant Failure Following SABR.

Authors:  Angela Davey; Marcel van Herk; Corinne Faivre-Finn; Alan McWilliam
Journal:  Front Oncol       Date:  2022-03-09       Impact factor: 6.244

7.  Adenoviral transduction of human acid sphingomyelinase into neo-angiogenic endothelium radiosensitizes tumor cure.

Authors:  Branka Stancevic; Nira Varda-Bloom; Jin Cheng; John D Fuller; Jimmy A Rotolo; Mónica García-Barros; Regina Feldman; Shyam Rao; Ralph R Weichselbaum; Dror Harats; Adriana Haimovitz-Friedman; Zvi Fuks; Michel Sadelain; Richard Kolesnick
Journal:  PLoS One       Date:  2013-08-02       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.